KRAS and neoplasm: TP53 [21], and RAS pathway mutations (KRAS, NRAS) are often identified in EMD patients [23,28,29], suggesting an upregulation of MAPK signaling [11], which has been associated with tumor-intrinsic immunosuppression [30].